Use of anti-haemophilia medicine suspended across Punjab after reports of adverse reactions

Faridkot:  The blood cell of the National Health Mission (NHM), Punjab, has directed all civil and district hospitals, as well as government medical colleges, to immediately suspend and quarantine all batches of anti-haemophilia Factor IX (600 IU) concentrate, manufactured by ICHOR Biologics Pvt Ltd following reports of adverse reactions in some patients after its administration.

The concentrate is a vital blood derivative used in the treatment and prevention of bleeding episodes in patients with Hemophilia B — a hereditary bleeding disorder caused by a deficiency of Factor IX, a protein essential for blood clotting.

The drug works by replacing the missing clotting factor, enabling normal blood coagulation and reducing the risk of prolonged bleeding.

According to official data, Punjab has around 550 registered hemophilia patients, though experts estimate this represents only about 7.4 per cent of the total cases in the state, suggesting that the actual number of people affected by the disorder may be significantly higher.

Guru Gobind Singh Medical College and Hospital, Faridkot, alone has about 100 registered patients with Hemophilia B.

In its advisory, the blood cell has instructed all nodal officers and in-charges of Integrated Centres for Hemoglobinopathies and Haemophilia (ICHH), as well as blood centres, to cease the use and administration of Anti-Haemophilia Factor IX 600 IU from all batches.

They have been asked to segregate and quarantine all existing stock at their respective facilities with immediate effect and maintain detailed records of quarantined stock and submit reports to the drug inspector concerned and the state blood cell office.

The batches currently under suspension are FN23005, FN24004, FN25006, FN25007, FN25009, and FN25013, according to the official order.

Authorities clarified that the suspension is a precautionary measure pending the outcome of laboratory testing by Punjab Health Systems Corporation (PHSC) to determine the safety and quality of the implicated product, said Dr Pardeep Kumar, Civil Surgeon, Moga.
Source : The Tribune

Related Posts

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Taro Pharmaceutical, a subsidiary of Sun Pharmaceutical, has initiated a recall of over 17,000 units of an antifungal shampoo in the United States after manufacturing issues were flagged by the…

Strides Pharma Science arm New York facility gets 4 USFDA observations

Bengaluru: Strides Pharma Science has announced that the U.S. Food and Drug Administration (USFDA) has concluded inspection with four observations at the Formulations Facility of Strides Pharma Inc. USA (SPI),…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

Strides Pharma Science arm New York facility gets 4 USFDA observations

Strides Pharma Science arm New York facility gets 4 USFDA observations

SSI Mantra, Made in India Robot, bats a Thousand by completing 100 Telesurgeries

SSI Mantra, Made in India Robot, bats a Thousand by completing 100 Telesurgeries

Bihar drug bust: Rs15 million narcotics seized in major trafficking crackdown

Bihar drug bust: Rs15 million narcotics seized in major trafficking crackdown

Top pharma companies racing to launch first weight-loss pill

Top pharma companies racing to launch first weight-loss pill

Ajanta Pharma shares rise 5% on Biocon weight-loss drug marketing pact

Ajanta Pharma shares rise 5% on Biocon weight-loss drug marketing pact